Importantly, inhibiting the SMYD3/CDCP1/Src axis deactivates CAFs, curbs hepatic metastatic outgrowth, and sensitizes tumors to oxaliplatin, nominating this pathway as a clinically actionable vulnerability in CRC. This evidence concerns the gene SMYD3 and colorectal carcinoma.